Ironwood Pharmaceuticals (NASDAQ:IRWD) Issues Quarterly Earnings Results

by · The Markets Daily

Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01), FiscalAI reports. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.The firm had revenue of $113.04 million during the quarter, compared to the consensus estimate of $114.84 million.

Here are the key takeaways from Ironwood Pharmaceuticals’ conference call:

  • LINZESS delivered strong momentum: Q2 U.S. net sales rose 14% year over year to $282.3 million, supported by mid-single-digit prescription growth and improved net pricing. Ironwood raised its 2026 LINZESS sales outlook to $1.15 billion–$1.20 billion, implying growth of more than 30% and a return to blockbuster status.
  • The FDA approved LINZESS for functional constipation in pediatric patients aged two and older, making it the only prescription therapy approved for this age group and expanding the brand’s addressable patient population.
  • Ironwood initiated active enrollment in the confirmatory Phase III STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure. Management believes the once-weekly therapy’s efficacy, tolerability, and potential to reduce parenteral-support dependence could support a best-in-class profile, though enrollment remains an execution priority.
  • Q2 GAAP net income was $51 million and adjusted EBITDA was $83 million; full-year revenue guidance increased to $460 million–$485 million and adjusted EBITDA guidance to above $310 million. The company repaid $200 million of convertible notes and expects gross debt below $300 million and leverage below 1x by year-end.
  • R&D spending is expected to rise in the second half as STARS-2 enrollment and site activation ramp, with modestly higher SG&A also anticipated. The ultimate expense increase will depend on how quickly additional trial sites are brought online.

Ironwood Pharmaceuticals Stock Up 1.4%

NASDAQ:IRWD traded up $0.06 during mid-day trading on Friday, reaching $4.32. The company’s stock had a trading volume of 1,842,560 shares, compared to its average volume of 2,179,845. Ironwood Pharmaceuticals has a 1 year low of $0.81 and a 1 year high of $5.78. The stock has a fifty day moving average of $3.90 and a 200-day moving average of $3.97. The firm has a market capitalization of $704.41 million, a PE ratio of 5.61 and a beta of 0.20.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IRWD shares. Wall Street Zen cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Friday, July 24th. Finally, Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.23.

Read Our Latest Report on IRWD

Insider Activity at Ironwood Pharmaceuticals

In related news, insider Ronald Silver sold 127,890 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the transaction, the insider directly owned 313,680 shares of the company’s stock, valued at $1,417,833.60. This trade represents a 28.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Julie Mchugh sold 21,571 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $3.73, for a total transaction of $80,459.83. Following the completion of the transaction, the director directly owned 250,749 shares of the company’s stock, valued at $935,293.77. This trade represents a 7.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 9.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its holdings in Ironwood Pharmaceuticals by 248.3% in the third quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock worth $15,321,000 after acquiring an additional 8,337,672 shares in the last quarter. Millennium Management LLC grew its position in Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. AQR Capital Management LLC increased its stake in Ironwood Pharmaceuticals by 144.3% during the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock valued at $4,422,000 after purchasing an additional 3,641,762 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Ironwood Pharmaceuticals by 616.3% in the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company’s stock worth $2,875,000 after buying an additional 3,436,036 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of Ironwood Pharmaceuticals by 740.5% in the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock worth $5,160,000 after buying an additional 3,092,475 shares during the last quarter.

About Ironwood Pharmaceuticals

(Get Free Report)

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.

Featured Stories